| Literature DB >> 30995480 |
Yingying Han1, Javier Mora2, Arnaud Huard3, Priscila da Silva3, Svenja Wiechmann4, Mateusz Putyrski5, Christian Schuster3, Eiman Elwakeel3, Guangping Lang6, Anica Scholz3, Tatjana Scholz7, Tobias Schmid3, Natasja de Bruin5, Pierre Billuart8, Carlo Sala9, Harald Burkhardt10, Michael J Parnham5, Andreas Ernst4, Bernhard Brüne11, Andreas Weigert12.
Abstract
Interleukin-38 (IL-38) is a cytokine of the IL-1 family with a role in chronic inflammation. However, its main cellular targets and receptors remain obscure. IL-38 is highly expressed in the skin and downregulated in psoriasis patients. We report an investigation in cellular targets of IL-38 during the progression of imiquimod-induced psoriasis. In this model, IL-38 knockout (IL-38 KO) mice show delayed disease resolution with exacerbated IL-17-mediated inflammation, which is reversed by the administration of mature IL-38 or γδ T cell-receptor-blocking antibodies. Mechanistically, X-linked IL-1 receptor accessory protein-like 1 (IL1RAPL1) is upregulated upon γδ T cell activation to feedforward-amplify IL-17 production and is required for IL-38 to suppress γδ T cell IL-17 production. Accordingly, psoriatic IL1RAPL1 KO mice show reduced inflammation and IL-17 production by γδ T cells. Our findings indicate a role for IL-38 in the regulation of γδ T cell activation through IL1RAPL1, with consequences for auto-inflammatory disease.Entities:
Keywords: IL-17; IL-38; IL1RAPL1; inflammation; psoriasis; γδ T cells
Mesh:
Substances:
Year: 2019 PMID: 30995480 DOI: 10.1016/j.celrep.2019.03.082
Source DB: PubMed Journal: Cell Rep Impact factor: 9.423